Log In
Print this Print this

Oral Relistor, methylnaltrexone (MOA-728)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (MOR; OPRM1) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in non-cancer patients with chronic pain
Regulatory Designation
Partner Lupin Ltd.; Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today